Cargando…

Effective Component Compatibility of Bufei Yishen Formula III Which Regulates the Mucus Hypersecretion of COPD Rats via the miR-146a-5p/EGFR/MEK/ERK Pathway

BACKGROUND: The effective-component compatibility of Bufei Yishen formula III (ECC-BYF III) with 5 ingredients (ginsenoside Rh1, astragaloside, icariin, nobiletin, and paeonol) has been shown to protect against chronic obstructive pulmonary disease (COPD). The present study aimed to observe the effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Jindi, Liu, Xuefang, Wei, Yumeng, Lu, Ruilong, Xu, Kexin, Tian, Yange, Li, Jiansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812609/ https://www.ncbi.nlm.nih.gov/pubmed/36619199 http://dx.doi.org/10.1155/2022/9423435

Ejemplares similares

Effective-compound combination of Bufei Yishen formula III combined with ER suppress airway mucus hypersecretion in COPD rats: via EGFR/MAPK signaling
por: Xu, Kexin, et al.
Publicado: (2023)

Effects and Mechanism of Bufei Yishen Formula in a Rat Chronic Obstructive Pulmonary Disease Model
por: Li, Jiansheng, et al.
Publicado: (2014)

Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease
por: Li, Jiansheng, et al.
Publicado: (2015)

Bufei Yishen Formula Restores Th17/Treg Balance and Attenuates Chronic Obstructive Pulmonary Disease via Activation of the Adenosine 2a Receptor
por: Zhao, Peng, et al.
Publicado: (2020)

Effect of Bufei Yishen Granules Combined with Electroacupuncture in Rats with Chronic Obstructive Pulmonary Disease via the Regulation of TLR-4/NF-κB Signaling
por: Ma, Jindi, et al.
Publicado: (2019)

Effective-Component Compatibility of Bufei Yishen Formula III Combined with Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic Obstructive Pulmonary Disease via Regulating SIRT1/NF-κB Signaling
por: Jin, Fanli, et al.
Publicado: (2022)

Identification of Metabolites and Metabolic Pathways Related to Treatment with Bufei Yishen Formula in a Rat COPD Model Using HPLC Q-TOF/MS
por: Yang, Liping, et al.
Publicado: (2015)

Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease
por: Zhao, Peng, et al.
Publicado: (2018)

System biology analysis of long-term effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profiling
por: Li, Jiansheng, et al.
Publicado: (2016)

Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS
por: Wu, Jinyan, et al.
Publicado: (2022)

Bufei Yishen granule combined with acupoint sticking improves pulmonary function and morphormetry in chronic obstructive pulmonary disease rats
por: Tian, Yange, et al.
Publicado: (2015)

Bufei Yishen Granules Combined with Acupoint Sticking Therapy Suppress Inflammation in Chronic Obstructive Pulmonary Disease Rats: Via JNK/p38 Signaling Pathway
por: Tian, Yange, et al.
Publicado: (2017)

Effects of Bufei Yishen Granules Combined with Acupoint Sticking Therapy on Pulmonary Surfactant Proteins in Chronic Obstructive Pulmonary Disease Rats
por: Tian, Yange, et al.
Publicado: (2016)

Bufei Yishen Formula Inhibits the Cell Senescence in COPD by Up-Regulating the ZNF263 and Klotho Expression
por: Wang, Weimin, et al.
Publicado: (2023)

Effective-component compatibility of Bufei Yishen formula III ameliorated COPD by improving airway epithelial cell senescence by promoting mitophagy via the NRF2/PINK1 pathway
por: Li, Min-yan, et al.
Publicado: (2022)

Combining systems pharmacology, transcriptomics, proteomics, and metabolomics to dissect the therapeutic mechanism of Chinese herbal Bufei Jianpi formula for application to COPD
por: Zhao, Peng, et al.
Publicado: (2016)

Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD
por: Zhao, Peng, et al.
Publicado: (2015)

Integrating Transcriptomics, Proteomics, and Metabolomics Profiling with System Pharmacology for the Delineation of Long-Term Therapeutic Mechanisms of Bufei Jianpi Formula in Treating COPD
por: Zhao, Peng, et al.
Publicado: (2017)

Sequential Treatments with Tongsai and Bufei Yishen Granules Reduce Inflammation and Improve Pulmonary Function in Acute Exacerbation-Risk Window of Chronic Obstructive Pulmonary Disease in Rats
por: Lu, Xiaofan, et al.
Publicado: (2016)

Bronchial Thermoplasty for Severe Asthma with Mucus Hypersecretion
por: Nagano, Naoko, et al.
Publicado: (2019)

Association of the CFTR gene with asthma and airway mucus hypersecretion
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2021)

Discovery of a drug to treat airway mucus hypersecretion
por: Dickey, Burton F., et al.
Publicado: (2022)

Bufei Jianpi Granules Reduce Quadriceps Muscular Cell Apoptosis by Improving Mitochondrial Function in Rats with Chronic Obstructive Pulmonary Disease
por: Mao, Jing, et al.
Publicado: (2019)

Azithromycin Inhibits Mucus Hypersecretion from Airway Epithelial Cells
por: Shimizu, Takeshi, et al.
Publicado: (2012)

Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
por: Stott-Miller, Marni, et al.
Publicado: (2020)

Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion
por: Tesfaigzi, Yohannes, et al.
Publicado: (2006)

Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms
por: Khan, Mohsin Ali, et al.
Publicado: (2021)

Ciliary dyskinesia in severe asthma is not affected by chronic mucus hypersecretion
por: Kempeneers, Céline, et al.
Publicado: (2023)

Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment
por: Shah, Binay Kumar, et al.
Publicado: (2023)

Bufei Jianpi Formula Improves Mitochondrial Function and Suppresses Mitophagy in Skeletal Muscle via the Adenosine Monophosphate-Activated Protein Kinase Pathway in Chronic Obstructive Pulmonary Disease
por: Mao, Jing, et al.
Publicado: (2020)

The Bufei Jianpi Formula Improves Mucosal Immune Function by Remodeling Gut Microbiota Through the SCFAs/GPR43/NLRP3 Pathway in Chronic Obstructive Pulmonary Disease Rats
por: Mao, Jing, et al.
Publicado: (2022)

Mucus Hypersecretion and Ciliary Impairment in Conducting Airway Contribute to Alveolar Mucus Plugging in Idiopathic Pulmonary Fibrosis
por: Peng, Yang, et al.
Publicado: (2022)

Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study
por: Dijkstra, Akkelies E., et al.
Publicado: (2014)

Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease
por: Tian, Pan-wen, et al.
Publicado: (2015)

Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion
por: Kim, Michael D., et al.
Publicado: (2021)

Bufei Jianpi granules improve skeletal muscle and mitochondrial dysfunction in rats with chronic obstructive pulmonary disease
por: Dong, Yuqiong, et al.
Publicado: (2015)

Correction: Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study
por: Dijkstra, Akkelies E., et al.
Publicado: (2015)

Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation
por: Jang, Sunhyae, et al.
Publicado: (2012)

Neutrophil extracellular traps promote lipopolysaccharide-induced airway inflammation and mucus hypersecretion in mice
por: Zou, Yong, et al.
Publicado: (2018)

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Yu, Suyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4jgudets9k3mndf9ah3gvb56lu